SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales is pegged at Rs. 3374.07 millions for the December 2024 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 3831.53 millions during the year-ago period.A comparatively good net profit growth of 40.30% to Rs. 411.68 millions was reported for the quarter ended December 2024 compared to Rs. 293.43 millions of previous same quarter.Operating Profit saw a handsome growth to 678.68 millions from 566.09 millions in the quarter ended December 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202412 202312 % Var
Sales 3374.07 3831.53 -11.94 3374.07 3831.53 -11.94 3374.07 3831.53 -11.94
Other Income 338.42 248.91 35.96 338.42 248.91 35.96 338.42 248.91 35.96
PBIDT 678.68 566.09 19.89 678.68 566.09 19.89 678.68 566.09 19.89
Interest 22.94 48.41 -52.61 22.94 48.41 -52.61 22.94 48.41 -52.61
PBDT 655.74 517.68 26.67 655.74 517.68 26.67 655.74 517.68 26.67
Depreciation 106.83 83.11 28.54 106.83 83.11 28.54 106.83 83.11 28.54
PBT 548.91 434.57 26.31 548.91 434.57 26.31 548.91 434.57 26.31
TAX 137.23 141.14 -2.77 137.23 141.14 -2.77 137.23 141.14 -2.77
Deferred Tax 6.66 -21.00 -131.71 6.66 -21.00 -131.71 6.66 -21.00 -131.71
PAT 411.68 293.43 40.30 411.68 293.43 40.30 411.68 293.43 40.30
Equity 306.21 286.13 7.02 306.21 286.13 7.02 306.21 286.13 7.02
PBIDTM(%) 20.11 14.77 36.14 20.11 14.77 36.14 20.11 14.77 36.14

Akums Drugs & Pharma Share Price

533.60 -0.50 (-0.09%)
22-Apr-2026 10:27 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1657.45
Dr. Reddys Lab 1212.50
Cipla 1228.00
Zydus Lifesciences 927.55
Lupin 2307.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×